Meeting
2013 ASCO Annual Meeting
The frequencies and clinical implications of mutations in 33 kinase-related genes in locally advanced rectal cancer.
Authors
Khairun Izlinda Abdul Jalil
Department of Medical Oncology, Beaumont Hospital, Dublin 9, Dublin, Ireland
Khairun Izlinda Abdul Jalil , Katherine M Sheehan , Sinead Toomey , Jasmin Schmid , Anthony O'grady , Robert Cummins , Brian O'Neill , Deborah A McNamara , Joseph Deasy , William Grogan , Oscar S. Breathnach , Ailin Rogers , Glen Doherty , Des C Winter , David Gibbons , John Ryan , Kieran Sheahan , Peter Gillen , Elaine Kay , Bryan Hennessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3549)
DOI
10.1200/jco.2013.31.15_suppl.3549
Abstract #
3549
Poster Bd #
2G
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock
Poster
2017 ASCO Annual Meeting
Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPECCT study.
First Author: Michael Boedigheimer
Poster
2020 Gastrointestinal Cancers Symposium
Clinical utility of targeted next generation sequencing (NGS) to predict response to neoadjuvant therapy (NT) in rectal cancer (RC).
First Author: Kristen Carroll
Poster
2017 Gastrointestinal Cancers Symposium
Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.
First Author: Gemma Bruera